Replies to post #80 on Avid Bioservices Inc (CDMO)

[DewDiligence]

FWIW: here is my handicapping of the Erbitux review:

1. Approval: 68%
--1a) Unconditional approval: 26%
--1b) Approval restricted to contract manufacturer (no use of in-house plant): 42%

2. Approvable letter: 18%
--2a) More clinical work needed: 11%
--2b) Issues can be resolved without more clinical work: 7%

3. FDA requests an extension: 13%

4. Rejection: 1%